MAM
HRTX icon

Meeder Asset Management’s Heron Therapeutics HRTX Stock Holding History

Meeder Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-110
Closed -$1K – 2229
2020
Q1 		$1K Sell
110
-313
-74% -$5.88K ﹤0.01% 2193
2019
Q4 		$10K Buy
423
+416
+5,943% +$9.2K ﹤0.01% 1557
2019
Q3 		$0 Hold
7
– – ﹤0.01% 2196
2019
Q2 		$0 Buy
+7
New +$140 ﹤0.01% 2076
2018
Q3 		– Sell
-141
Closed -$5.48K – 1606
2018
Q2 		$5.48K Buy
+141
New +$4.49K ﹤0.01% 1256
2017
Q2 		– Sell
-407
Closed -$6K – 1753
2017
Q1 		$6K Buy
407
+8
+2% +$111 ﹤0.01% 1006
2016
Q4 		$5K Buy
+399
New +$6.26K ﹤0.01% 855

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Meeder Asset Management's HRTX Position: Q2 2020 in Review

Meeder Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 110 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in HRTX in Q4 2016 and held it in 7 quarters. The position peaked at $10K in Q4 2019. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

  • Meeder Asset Management reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 110 Heron Therapeutics shares in Q2 2020, an estimated $1K.
  • Meeder Asset Management first reported a position in Heron Therapeutics in Q4 2016 and held it in 7 quarters.
  • Meeder Asset Management's Heron Therapeutics position peaked at $10K in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.